Novel Breast Probe Reduces Repeat Breast Cancer Surgeries

Publication
Article
OncologyONCOLOGY Vol 22 No 6
Volume 22
Issue 6

A novel intraoperative breast cancer probe is showing significant promise in the reduction of repeat procedures in patients undergoing breast-conserving surgeries, according to a study presented at the ASBS meeting.

A novel intraoperative breast cancer probe is showing significant promise in the reduction of repeat procedures in patients undergoing breast-conserving surgeries, according to a study presented at the ASBS meeting. Using radiofrequency spectroscopy technology, the handheld MarginProbe (Dune Medical Devices, Caesarea, Israel) assesses margin malignancy status during an initial lumpectomy and helps avoid repeat procedures by enabling doctors to intraoperatively identify positive margins. Currently, positive tumor margins are identified through postoperative pathology results and are typically corrected with second surgeries, incurring added patient complication and expense.

The 300-patient randomized clinical trial conducted in 11 Israeli medical centers underscored the safety and clinical benefit of the MarginProbe system in the intraoperative detection of tumors at the resection margins in patients undergoing breast-conservation surgery. The study compared the performance of 35 surgeons operating on patients with and without use of the device. Use of the probe resulted in a 56% reduction in repeat lumpectomies. No statistically significant difference between the two study arms was seen in the volume of tissue removed.

More Precise Surgery
“This data is significant in demonstrating the potential of radiofrequency spectroscopy and the probe in characterization of cancer at the resection margins and in guiding surgeons towards more precise surgical interventions,” said study investigator Tanir Allweis, MD, of Hadassah Hebrew University Medical Center, Jerusalem. “The reduction of patient complications and discomfort as well as costs associated with repeat breast surgeries is of significant benefit to everyone involved in the treatment of breast disease.”

The device consists of a sterile, handheld probe and portable console. As the tip of the probe is applied to excised lumpectomy tissue, radiofrequency signals are transmitted into the tissue. After the signals are reflected back to the console, they are analyzed based on a specialized algorithm to determine the presence of malignant tissue in the measured area adjacent to the probe tip.

 

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.